Company intelligence / Profile preview
Avantogen Limited
Sydney, NSW, Australiaavantgen.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Prior to its merger with Hawaii Biotech in May/June of 2006, Avantogen was developing a broad portfolio of oncology drugs and had advanced a vaccine adjuvant program into Phase I human trials and the Pentrys vaccine program into Phase II human trials. Post-merger activities continued under the Hawaii Biotech name.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small moleculesVaccines/adjuvants
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Merged/commercial partnership with Hawaii Biotech Inc.Received significant funding from NIH and other government agencies for infectious disease vaccines.
Beyond the preview
Go deeper on Avantogen Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avantogen Limited.